Literature DB >> 16174803

Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6.

Kari E Dicke1, Sara M Skrlin, Sharon E Murphy.   

Abstract

Nicotine is the major addictive agent in tobacco; it is primarily metabolized by 5'-oxidation. 4-(Methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK), a potent lung carcinogen generated from nicotine during the curing of tobacco, is metabolically activated by P450 enzymes. P450 2A6 is the primary hepatic catalyst of nicotine metabolism and also catalyzes NNK alpha-hydroxylation, albeit less efficiently. It was previously reported that P450 2B6 catalyzed nicotine 5'-oxidation. The studies presented here investigate the relative importance of P450 2B6 as a catalyst of nicotine 5'-oxidation and NNK alpha-hydroxylation by human liver microsomes (HLMs). Radioflow high-performance liquid chromatography analysis and tritiated substrates were used to monitor the products of nicotine and NNK metabolism. The primary product of P450 2B6-catalyzed nicotine metabolism was the delta1'(5') iminium ion. The only other metabolite detected was nornicotine, the product of methyl oxidation, formed at about one-fourth the rate of the delta1' (5') iminium ion. We determined that P450 2B6 was a much less efficient catalyst of nicotine 5'-oxidation than previously reported, with an estimated K(m) of 820 microM. In contrast, the K(m) of NNK alpha-hydroxylation was 33 muM. Experiments with P450 2A6- and P450 2B6-selective inhibitory antibodies did not support P450 2B6 as a significant catalyst of nicotine 5'-oxidation by HLMs, and it is unlikely that this enzyme contributes to nicotine metabolism in smokers who express P450 2A6. However, P450 2B6 contributed significantly to NNK metabolism in HLMs expressing both P450 2B6 and P450 2A6, suggesting a possible role for P450 2B6 in NNK metabolic activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174803     DOI: 10.1124/dmd.105.006718

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 2.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 3.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

4.  Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.

Authors:  Anna M Lee; Sharon Miksys; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

5.  CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.

Authors:  Jian-Min Yuan; Heather H Nelson; Steven G Carmella; Renwei Wang; Jacquelyn Kuriger-Laber; Aizhen Jin; Jennifer Adams-Haduch; Stephen S Hecht; Woon-Puay Koh; Sharon E Murphy
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

6.  Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo.

Authors:  Zhihua Liu; Lei Li; Hong Wu; Jing Hu; Jun Ma; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2014-11-19       Impact factor: 3.922

Review 7.  Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Authors:  Anusha Ande; Carole McArthur; Anil Kumar; Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-07-04       Impact factor: 4.481

8.  Effect of CYP2A13 active site mutation N297A on metabolism of coumarin and tobacco-specific nitrosamines.

Authors:  Kari E Schlicht; Jeannette Zinggeler Berg; Sharon E Murphy
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

9.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

Review 10.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.